Impax Pharmaceuticals was awarded a Michael J. Fox Foundation Grant for Ongoing Research of IPX066 for Parkinson's Disease last month.

According to the press release,

"The funding will support a planned dosing conversion study of CD-LD ER to IPX066, to be followed by an open-label extension safety study of IPX066 in subjects with advanced PD.

"One of our priorities is to improve symptomatic treatments for patients today," said Brian Fiske, Ph.D., director of research programs at the Michael J. Fox Foundation. "IPX066 holds promise as a potentially useful future treatment option for PD. By collaborating with Impax Pharmaceuticals to develop additional clinical data about IPX066, we hope to gather important information for physicians treating PD and their patients."

Perhaps writing to Dr. Fiske at the Michael J. Fox Foundation will help persuade Impax to revise their decision on denying access to IPX066 to participants in earlier trials.